// App-Quantinova.ai

PD5-09 : Prognostic and predictive impact of genes and signatures measured with the BC360 panel (Nanostring) in node positive (≥pN2a) high risk patients (pts) receiving dose dense (dd) versus standard dosed chemotherapy in an adjuvant randomized trial with a long term follow-up (FU)

Researchers

Presenter

  • Mattea Reinisch

Principal Investigators

  • Oleg Gluz

  • Beyhan Ataseven

  • Peter Schmid

  • Jens-Uwe Blohmer

  • Christine Dittmer-Grabwoski

  • Anna Rueland

  • Simona Bruzas

  • Christine Seiberling

  • Hakima Harrach

  • Daniel Gebauer

  • Alexander Traut

  • Sherko Kuemmel

Medical Centers

  • AGO & Kliniken Essen Mitte, Essen, Germany

  • Ev. Bethesda Hospital, Moenchengladbach, NRW, Germany

  • Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • Charite Berlin, Berlin, Germany

  • Institute for Pathology, Viersen, Germany

Locations

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Adrucil injection

  • Fluorouracil

  • Methotrexate

  • Epirubicin

  • Paclitaxel

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved